Comparison of Surgical Outcomes Between Invasive Mucinous and Non-Mucinous Lung Adenocarcinoma
Invasive mucinous adenocarcinoma (IMA) is a rare subtype of invasive lung adenocarcinoma. However, the clinical course and prognostic outcomes following IMA resection, particularly postoperative recurrence, remain unclear. We pathologically reevaluated 1362 lung adenocarcinoma resections performed a...
Saved in:
Published in | The Annals of thoracic surgery Vol. 112; no. 4; pp. 1118 - 1126 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Inc
01.10.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Invasive mucinous adenocarcinoma (IMA) is a rare subtype of invasive lung adenocarcinoma. However, the clinical course and prognostic outcomes following IMA resection, particularly postoperative recurrence, remain unclear.
We pathologically reevaluated 1362 lung adenocarcinoma resections performed at our institution, categorizing cases into the IMA group (72 cases) and non-IMA group (1290 cases). The IMA group was further classified into pneumonia and nodular types based on preoperative computed tomography.
Overall, the IMA group had lower carcinoembryonic antigen levels (3 vs 8 ng/mL; P < .01), fewer lymph node metastasis (4% vs 24%; P < .01), and more KRAS mutations (56% vs 7%; P < .01) than the non-IMA group. Although postoperative recurrence rates did not differ between both groups (32% vs 27%; P = 0.35), lung recurrence occurred more frequently in the IMA group (83% vs 17%; P < .01). Propensity score-matched pair analysis showed that the IMA group had fewer lymph node metastasis (3% vs 35%; P < .01), more KRAS mutations (56% vs 9%; P < .01), and higher intrapulmonary recurrence rate (84% vs 31%; P < .01) than the non-IMA group. The 5-year overall survival rates did not differ between both groups (74% vs 81%; P = 0.26). However, among patients with intrapulmonary recurrence, those in the IMA group had significantly worse prognosis than those in the non-IMA group (35% vs 77%; P < .01).
Intrapulmonary recurrence, which induced significantly worse prognosis, was more likely to occur in the IMA than non-IMA group.
[Display omitted] |
---|---|
AbstractList | Invasive mucinous adenocarcinoma (IMA) is a rare subtype of invasive lung adenocarcinoma. However, the clinical course and prognostic outcomes following IMA resection, particularly postoperative recurrence, remain unclear.
We pathologically reevaluated 1362 lung adenocarcinoma resections performed at our institution, categorizing cases into the IMA group (72 cases) and non-IMA group (1290 cases). The IMA group was further classified into pneumonia and nodular types based on preoperative computed tomography.
Overall, the IMA group had lower carcinoembryonic antigen levels (3 vs 8 ng/mL; P < .01), fewer lymph node metastasis (4% vs 24%; P < .01), and more KRAS mutations (56% vs 7%; P < .01) than the non-IMA group. Although postoperative recurrence rates did not differ between both groups (32% vs 27%; P = 0.35), lung recurrence occurred more frequently in the IMA group (83% vs 17%; P < .01). Propensity score-matched pair analysis showed that the IMA group had fewer lymph node metastasis (3% vs 35%; P < .01), more KRAS mutations (56% vs 9%; P < .01), and higher intrapulmonary recurrence rate (84% vs 31%; P < .01) than the non-IMA group. The 5-year overall survival rates did not differ between both groups (74% vs 81%; P = 0.26). However, among patients with intrapulmonary recurrence, those in the IMA group had significantly worse prognosis than those in the non-IMA group (35% vs 77%; P < .01).
Intrapulmonary recurrence, which induced significantly worse prognosis, was more likely to occur in the IMA than non-IMA group.
[Display omitted] Invasive mucinous adenocarcinoma (IMA) is a rare subtype of invasive lung adenocarcinoma. However, the clinical course and prognostic outcomes following IMA resection, particularly postoperative recurrence, remain unclear.BACKGROUNDInvasive mucinous adenocarcinoma (IMA) is a rare subtype of invasive lung adenocarcinoma. However, the clinical course and prognostic outcomes following IMA resection, particularly postoperative recurrence, remain unclear.We pathologically reevaluated 1362 lung adenocarcinoma resections performed at our institution, categorizing cases into the IMA group (72 cases) and non-IMA group (1290 cases). The IMA group was further classified into pneumonia and nodular types based on preoperative computed tomography.METHODSWe pathologically reevaluated 1362 lung adenocarcinoma resections performed at our institution, categorizing cases into the IMA group (72 cases) and non-IMA group (1290 cases). The IMA group was further classified into pneumonia and nodular types based on preoperative computed tomography.Overall, the IMA group had lower carcinoembryonic antigen levels (3 vs 8 ng/mL; P < .01), fewer lymph node metastasis (4% vs 24%; P < .01), and more KRAS mutations (56% vs 7%; P < .01) than the non-IMA group. Although postoperative recurrence rates did not differ between both groups (32% vs 27%; P = 0.35), lung recurrence occurred more frequently in the IMA group (83% vs 17%; P < .01). Propensity score-matched pair analysis showed that the IMA group had fewer lymph node metastasis (3% vs 35%; P < .01), more KRAS mutations (56% vs 9%; P < .01), and higher intrapulmonary recurrence rate (84% vs 31%; P < .01) than the non-IMA group. The 5-year overall survival rates did not differ between both groups (74% vs 81%; P = 0.26). However, among patients with intrapulmonary recurrence, those in the IMA group had significantly worse prognosis than those in the non-IMA group (35% vs 77%; P < .01).RESULTSOverall, the IMA group had lower carcinoembryonic antigen levels (3 vs 8 ng/mL; P < .01), fewer lymph node metastasis (4% vs 24%; P < .01), and more KRAS mutations (56% vs 7%; P < .01) than the non-IMA group. Although postoperative recurrence rates did not differ between both groups (32% vs 27%; P = 0.35), lung recurrence occurred more frequently in the IMA group (83% vs 17%; P < .01). Propensity score-matched pair analysis showed that the IMA group had fewer lymph node metastasis (3% vs 35%; P < .01), more KRAS mutations (56% vs 9%; P < .01), and higher intrapulmonary recurrence rate (84% vs 31%; P < .01) than the non-IMA group. The 5-year overall survival rates did not differ between both groups (74% vs 81%; P = 0.26). However, among patients with intrapulmonary recurrence, those in the IMA group had significantly worse prognosis than those in the non-IMA group (35% vs 77%; P < .01).Intrapulmonary recurrence, which induced significantly worse prognosis, was more likely to occur in the IMA than non-IMA group.CONCLUSIONSIntrapulmonary recurrence, which induced significantly worse prognosis, was more likely to occur in the IMA than non-IMA group. |
Author | Sakakura, Noriaki Hosoda, Waki Murakami, Yoshiko Sasaki, Eiichi Yatabe, Yasushi Kato, Seiichi Kuroda, Hiroaki Koyama, Shin Nakanishi, Keita Matsui, Takuya |
Author_xml | – sequence: 1 givenname: Takuya surname: Matsui fullname: Matsui, Takuya organization: Department of Thoracic Surgery, Aichi Cancer Center, Nagoya, Japan – sequence: 2 givenname: Noriaki surname: Sakakura fullname: Sakakura, Noriaki email: nsakakura@aichi-cc.jp organization: Department of Thoracic Surgery, Aichi Cancer Center, Nagoya, Japan – sequence: 3 givenname: Shin surname: Koyama fullname: Koyama, Shin organization: Department of Thoracic Surgery, Aichi Cancer Center, Nagoya, Japan – sequence: 4 givenname: Keita surname: Nakanishi fullname: Nakanishi, Keita organization: Department of Thoracic Surgery, Aichi Cancer Center, Nagoya, Japan – sequence: 5 givenname: Eiichi surname: Sasaki fullname: Sasaki, Eiichi organization: Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan – sequence: 6 givenname: Seiichi surname: Kato fullname: Kato, Seiichi organization: Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan – sequence: 7 givenname: Waki surname: Hosoda fullname: Hosoda, Waki organization: Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan – sequence: 8 givenname: Yoshiko surname: Murakami fullname: Murakami, Yoshiko organization: Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan – sequence: 9 givenname: Hiroaki surname: Kuroda fullname: Kuroda, Hiroaki organization: Department of Thoracic Surgery, Aichi Cancer Center, Nagoya, Japan – sequence: 10 givenname: Yasushi surname: Yatabe fullname: Yatabe, Yasushi organization: Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan |
BookMark | eNqNkc9P2zAUgK0JpJWy_8HHXZLZTuLGFzSoBkPqxmHjiuU-v4BLYne2U8R_v1SdmMSpJ7-fn54-n5ETHzwSQjkrOePyy6Y0-SlEA2mMpWCClUyVrBYfyIw3jSikaNQJmTHGqqJWi-YjOUtpM6Vias_IwzIMWxNdCp6Gjv4a46MD09O7MUMYMNErzC-Int76nUluh_THCM6HMVHjLf0ZfPFWWI3-kV5a9AFM3NcGc05OO9Mn_PTvnZP762-_l9-L1d3N7fJyVUDD21xIKzsUtjVyiuq1BJBrY1nHeCUXqrN1ZVUFCwGtRega3qgWOmGqdQXGKsGrOfl84G5j-DNiynpwCbDvjcfpNC1q2dQ1Z62aRtvDKMSQUsROb6MbTHzVnOm9Ur3R_5XqvVLNlJ6UTqsX71bBZZNd8Dka1x8DuDoAcHKxcxh1Aoce0LqIkLUN7hjI13cQ6J3f_9ozvh6H-AvDg7R1 |
CitedBy_id | crossref_primary_10_1007_s12262_023_03688_1 crossref_primary_10_1007_s11748_024_02103_0 crossref_primary_10_2147_IJGM_S479978 crossref_primary_10_1016_j_chpulm_2024_100104 crossref_primary_10_1186_s12957_024_03326_4 crossref_primary_10_1186_s12885_024_13068_x crossref_primary_10_1148_rg_230136 crossref_primary_10_1016_j_heliyon_2024_e30209 crossref_primary_10_1186_s12885_024_12714_8 crossref_primary_10_2214_AJR_22_28139 crossref_primary_10_1016_j_ejso_2024_108053 crossref_primary_10_1111_1759_7714_14687 crossref_primary_10_1080_14796694_2024_2405457 crossref_primary_10_1164_rccm_202301_0124IM crossref_primary_10_1038_s41598_024_69138_4 crossref_primary_10_1016_j_cllc_2024_05_004 crossref_primary_10_1007_s00432_022_04022_0 crossref_primary_10_1097_PAS_0000000000001938 crossref_primary_10_1177_15330338241308307 crossref_primary_10_1245_s10434_023_14193_w crossref_primary_10_1016_j_crad_2024_08_008 crossref_primary_10_1002_ccr3_7707 crossref_primary_10_1016_j_lungcan_2023_107348 crossref_primary_10_1016_j_trre_2023_100772 crossref_primary_10_1016_j_jtho_2024_11_016 crossref_primary_10_4103_jcrt_jcrt_2334_21 crossref_primary_10_1245_s10434_024_15541_0 crossref_primary_10_3390_ijms25158413 |
Cites_doi | 10.1016/j.lungcan.2013.06.012 10.1067/mtc.2001.110190 10.1097/JTO.0b013e318221f701 10.1016/j.lungcan.2016.11.004 10.1016/j.jtho.2016.03.011 10.1097/JTO.0b013e318206a221 10.1200/JCO.2012.46.9270 10.1002/cncr.26010 10.1038/modpathol.2010.232 10.1097/PAS.0b013e31826be303 10.1097/JTO.0b013e3182769aa8 10.1016/j.humpath.2013.05.026 10.1200/JCO.2005.19.240 10.1097/JTO.0000000000000630 10.1097/JTO.0000000000000579 10.1378/chest.123.6.1868 10.1097/PAS.0000000000000246 |
ContentType | Journal Article |
Copyright | 2021 The Society of Thoracic Surgeons Copyright © 2021 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2021 The Society of Thoracic Surgeons – notice: Copyright © 2021 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. |
DBID | AAYXX CITATION 7X8 |
DOI | 10.1016/j.athoracsur.2020.09.042 |
DatabaseName | CrossRef MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 1552-6259 |
EndPage | 1126 |
ExternalDocumentID | 10_1016_j_athoracsur_2020_09_042 S0003497520320014 |
GroupedDBID | --- --K .1- .55 .FO .GJ 0R~ 1B1 1P~ 1~5 23M 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 6J9 7-5 71M AAEDT AAEDW AAEJM AALRI AAQFI AAQQT AAQXK AAXUO ABJNI ABLJU ABMAC ABOCM ABWVN ACGFO ACGFS ACIUM ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AENEX AEUPX AEVXI AFFNX AFPUW AFRHN AFTJW AGCQF AGHFR AGQPQ AI. AIGII AITUG AJJEV AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP ASPBG AVWKF AZFZN BAWUL BELOY C5W CS3 DIK E3Z EBS EFJIC EFKBS EJD F5P FDB FEDTE FGOYB GBLVA GX1 HVGLF HZ~ IH2 IHE J1W J5H K-O KOM L7B M41 MO0 N9A NQ- O9- OA- OK1 OL. OVD P2P P6G PC. R2- ROL RPZ SES SSZ TEORI TR2 UDS UNMZH UV1 VH1 W8F X7M XH2 XPP Z5R ZGI ZXP AAIAV ACRZS ADPAM AFCTW AGZHU AHPSJ ALXNB RIG ZA5 AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c518t-6d6fe2d8a66d64b6cc6bad0f013679fd43d93c72c8decf51598cf2a3b3cad9213 |
ISSN | 0003-4975 1552-6259 |
IngestDate | Fri Jul 11 05:00:09 EDT 2025 Thu Apr 24 22:53:12 EDT 2025 Tue Jul 01 03:18:44 EDT 2025 Fri Feb 23 02:42:55 EST 2024 Tue Aug 26 16:47:53 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | ATS DFS CT IASLC BAC OS CI ERS IMA EGFR WHO |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c518t-6d6fe2d8a66d64b6cc6bad0f013679fd43d93c72c8decf51598cf2a3b3cad9213 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
PQID | 2465441089 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2465441089 crossref_primary_10_1016_j_athoracsur_2020_09_042 crossref_citationtrail_10_1016_j_athoracsur_2020_09_042 elsevier_sciencedirect_doi_10_1016_j_athoracsur_2020_09_042 elsevier_clinicalkey_doi_10_1016_j_athoracsur_2020_09_042 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | October 2021 2021-10-00 20211001 |
PublicationDateYYYYMMDD | 2021-10-01 |
PublicationDate_xml | – month: 10 year: 2021 text: October 2021 |
PublicationDecade | 2020 |
PublicationTitle | The Annals of thoracic surgery |
PublicationYear | 2021 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Yoshizawa, Motoi, Riely (bib7) 2011; 24 Tsuta, Kawago, Inoue (bib5) 2013; 81 Russell, Wainer, Wright (bib6) 2011; 6 Cha, Kim, Lee (bib17) 2016; 102 Travis, Brambilla, Nicholson (bib2) 2015; 10 Yoshizawa, Sumiyoshi, Sonobe (bib13) 2013; 8 Ichinokawa, Ishii, Nagai (bib16) 2013; 44 Travis, Brambilla, Gregory (bib3) 2013; 31 Miller, Hirsch, Johnson (bib12) 2005; 23 Sugano, Nagasaka, Sasaki (bib4) 2013; 37 Lee, Cha, Lee (bib9) 2016; 11 Travis, Brambilla, Noguchi (bib1) 2011; 6 Breathnach, Kwiatkowski, Finkelstein (bib10) 2001; 121 Kadota, Yeh, D’ Angelo (bib14) 2014; 38 Kakegawa, Shimizu, Sugano (bib15) 2011; 117 Shim, Mari-Kenudson, Zheng (bib8) 2015; 10 Wislez, Massiani, Milleron (bib11) 2003; 123 Ichinokawa (10.1016/j.athoracsur.2020.09.042_bib16) 2013; 44 Shim (10.1016/j.athoracsur.2020.09.042_bib8) 2015; 10 Miller (10.1016/j.athoracsur.2020.09.042_bib12) 2005; 23 Kadota (10.1016/j.athoracsur.2020.09.042_bib14) 2014; 38 Travis (10.1016/j.athoracsur.2020.09.042_bib2) 2015; 10 Russell (10.1016/j.athoracsur.2020.09.042_bib6) 2011; 6 Tsuta (10.1016/j.athoracsur.2020.09.042_bib5) 2013; 81 Yoshizawa (10.1016/j.athoracsur.2020.09.042_bib7) 2011; 24 Wislez (10.1016/j.athoracsur.2020.09.042_bib11) 2003; 123 Lee (10.1016/j.athoracsur.2020.09.042_bib9) 2016; 11 Sugano (10.1016/j.athoracsur.2020.09.042_bib4) 2013; 37 Breathnach (10.1016/j.athoracsur.2020.09.042_bib10) 2001; 121 Kakegawa (10.1016/j.athoracsur.2020.09.042_bib15) 2011; 117 Travis (10.1016/j.athoracsur.2020.09.042_bib1) 2011; 6 Yoshizawa (10.1016/j.athoracsur.2020.09.042_bib13) 2013; 8 Travis (10.1016/j.athoracsur.2020.09.042_bib3) 2013; 31 Cha (10.1016/j.athoracsur.2020.09.042_bib17) 2016; 102 |
References_xml | – volume: 6 start-page: 1496 year: 2011 end-page: 1504 ident: bib6 article-title: Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification publication-title: J Thorac Oncol – volume: 81 start-page: 371 year: 2013 end-page: 376 ident: bib5 article-title: The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations publication-title: Lung Cancer – volume: 6 start-page: 244 year: 2011 end-page: 285 ident: bib1 article-title: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma publication-title: J Thorac Oncol – volume: 123 start-page: 1868 year: 2003 end-page: 1877 ident: bib11 article-title: Clinical characteristics of pneumonic-type adenocarcinoma of the lung publication-title: Chest – volume: 102 start-page: 82 year: 2016 end-page: 88 ident: bib17 article-title: Clinical course of stage IV invasive mucinous adenocarcinoma of the lung publication-title: Lung Cancer – volume: 37 start-page: 211 year: 2013 end-page: 218 ident: bib4 article-title: HNF4α as a marker for invasive mucinous adenocarcinoma of the lung publication-title: Am J Surg Pathol – volume: 10 start-page: 1156 year: 2015 end-page: 1162 ident: bib8 article-title: Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung publication-title: J Thorac Oncol – volume: 23 start-page: 3288 year: 2005 end-page: 3293 ident: bib12 article-title: Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities publication-title: J Clin Oncol – volume: 121 start-page: 42 year: 2001 end-page: 47 ident: bib10 article-title: Bronchioloalveolar carcinoma of the lung: recurrence and survival in patients with stage I disease publication-title: J Thorac Cardiovasc Surg – volume: 8 start-page: 52 year: 2013 end-page: 61 ident: bib13 article-title: Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with publication-title: J Thorac Oncol – volume: 24 start-page: 653 year: 2011 end-page: 664 ident: bib7 article-title: Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases publication-title: Mod Pathol – volume: 31 start-page: 992 year: 2013 end-page: 1001 ident: bib3 article-title: New pathologic classification of lung cancer: relevance for clinical practice and clinical trials publication-title: J Clin Oncol – volume: 11 start-page: 1064 year: 2016 end-page: 1073 ident: bib9 article-title: Prognosis in resected invasive mucinous adenocarcinomas of the lung: related factors and comparison with resected nonmucinous adenocarcinomas publication-title: J Thorac Oncol – volume: 117 start-page: 4257 year: 2011 end-page: 4266 ident: bib15 article-title: Clinicopathological features of lung adenocarcinoma with publication-title: Cancer – volume: 44 start-page: 2636 year: 2013 end-page: 2642 ident: bib16 article-title: Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with publication-title: Hum Pathol – volume: 38 start-page: 1118 year: 2014 end-page: 1127 ident: bib14 article-title: Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with publication-title: Am J Surg Pathol – volume: 10 start-page: 1243 year: 2015 end-page: 1260 ident: bib2 article-title: The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification publication-title: J Thorac Oncol – volume: 81 start-page: 371 year: 2013 ident: 10.1016/j.athoracsur.2020.09.042_bib5 article-title: The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations publication-title: Lung Cancer doi: 10.1016/j.lungcan.2013.06.012 – volume: 121 start-page: 42 year: 2001 ident: 10.1016/j.athoracsur.2020.09.042_bib10 article-title: Bronchioloalveolar carcinoma of the lung: recurrence and survival in patients with stage I disease publication-title: J Thorac Cardiovasc Surg doi: 10.1067/mtc.2001.110190 – volume: 6 start-page: 1496 year: 2011 ident: 10.1016/j.athoracsur.2020.09.042_bib6 publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e318221f701 – volume: 102 start-page: 82 year: 2016 ident: 10.1016/j.athoracsur.2020.09.042_bib17 article-title: Clinical course of stage IV invasive mucinous adenocarcinoma of the lung publication-title: Lung Cancer doi: 10.1016/j.lungcan.2016.11.004 – volume: 11 start-page: 1064 year: 2016 ident: 10.1016/j.athoracsur.2020.09.042_bib9 article-title: Prognosis in resected invasive mucinous adenocarcinomas of the lung: related factors and comparison with resected nonmucinous adenocarcinomas publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2016.03.011 – volume: 6 start-page: 244 year: 2011 ident: 10.1016/j.athoracsur.2020.09.042_bib1 article-title: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e318206a221 – volume: 31 start-page: 992 year: 2013 ident: 10.1016/j.athoracsur.2020.09.042_bib3 article-title: New pathologic classification of lung cancer: relevance for clinical practice and clinical trials publication-title: J Clin Oncol doi: 10.1200/JCO.2012.46.9270 – volume: 117 start-page: 4257 year: 2011 ident: 10.1016/j.athoracsur.2020.09.042_bib15 article-title: Clinicopathological features of lung adenocarcinoma with KRAS mutations publication-title: Cancer doi: 10.1002/cncr.26010 – volume: 24 start-page: 653 year: 2011 ident: 10.1016/j.athoracsur.2020.09.042_bib7 article-title: Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases publication-title: Mod Pathol doi: 10.1038/modpathol.2010.232 – volume: 37 start-page: 211 year: 2013 ident: 10.1016/j.athoracsur.2020.09.042_bib4 article-title: HNF4α as a marker for invasive mucinous adenocarcinoma of the lung publication-title: Am J Surg Pathol doi: 10.1097/PAS.0b013e31826be303 – volume: 8 start-page: 52 year: 2013 ident: 10.1016/j.athoracsur.2020.09.042_bib13 article-title: Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e3182769aa8 – volume: 44 start-page: 2636 year: 2013 ident: 10.1016/j.athoracsur.2020.09.042_bib16 article-title: Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation publication-title: Hum Pathol doi: 10.1016/j.humpath.2013.05.026 – volume: 23 start-page: 3288 year: 2005 ident: 10.1016/j.athoracsur.2020.09.042_bib12 article-title: Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities publication-title: J Clin Oncol doi: 10.1200/JCO.2005.19.240 – volume: 10 start-page: 1243 year: 2015 ident: 10.1016/j.athoracsur.2020.09.042_bib2 article-title: The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification publication-title: J Thorac Oncol doi: 10.1097/JTO.0000000000000630 – volume: 10 start-page: 1156 year: 2015 ident: 10.1016/j.athoracsur.2020.09.042_bib8 article-title: Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung publication-title: J Thorac Oncol doi: 10.1097/JTO.0000000000000579 – volume: 123 start-page: 1868 year: 2003 ident: 10.1016/j.athoracsur.2020.09.042_bib11 article-title: Clinical characteristics of pneumonic-type adenocarcinoma of the lung publication-title: Chest doi: 10.1378/chest.123.6.1868 – volume: 38 start-page: 1118 year: 2014 ident: 10.1016/j.athoracsur.2020.09.042_bib14 article-title: Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation publication-title: Am J Surg Pathol doi: 10.1097/PAS.0000000000000246 |
SSID | ssj0002155 |
Score | 2.5040743 |
Snippet | Invasive mucinous adenocarcinoma (IMA) is a rare subtype of invasive lung adenocarcinoma. However, the clinical course and prognostic outcomes following IMA... |
SourceID | proquest crossref elsevier |
SourceType | Aggregation Database Enrichment Source Index Database Publisher |
StartPage | 1118 |
Title | Comparison of Surgical Outcomes Between Invasive Mucinous and Non-Mucinous Lung Adenocarcinoma |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0003497520320014 https://dx.doi.org/10.1016/j.athoracsur.2020.09.042 https://www.proquest.com/docview/2465441089 |
Volume | 112 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELbK9sILAgFiMJCR9jYFJc6PxuJpTKCxsSKxTuwJy7EdLR1LUZsgjX-Ef5ezYzvpVETZS5Q4OrfOffl8vpzvENrLkkzkMi-DhHAZJEpFAU2JDKKcSl0caaxMyP_pJDs6T44v0ovR6Pcgaqltijfi19p9JXfRKrSBXvUu2f_QrO8UGuAc9AtH0DAcN9Lx4bCIIHDAoqOxz20Dv6aW--9sENbH-ic3YeqnrahMTlbtLp_M68A3fGq1ewRICOa2hW6zfD3r0dTnWm4uATiiEvvLwaZq49Zulq0JD5jyq_bGM_4Zv4JrU9FIfyiqwGr1RD-_4dfmxtll5YE6AYFae8e6rUNVw4feCRL5OLeecWNdxS5dYdyIDKCVDPgTmDcfzMV6f9Nanu9cDjN43GbAMFpY6pPQpKztsnWtpta-NeX5QEQX4zZjfU9M98RCyqCne2ibwPoDCHT74OTL1xM_yYOllLpijHp4NkisCx1c_6_-ZvncsgGMYTN9iB7YFQk-6OD1CI1U_Rh966GF5yV20MIOWthCCztoYYckDNDCQ2hhDS28Cq0n6PzD--nhUWBLcQQijfImyGRWKiJznsFZUmRCZAWXYWky_tFSJrGksRgTeO-VKLWNnIuS8LiIBZeURPFTtFXPa_UMYbCGYAJWMpWpShQpaFgqqmClXohQJ6ndQWP3mJiweep1uZTv7F_K2kGRl_zR5WrZQIY6TTC3FxlmTwZA20D2rZe19mpnh24o_dopngGl6-90vFagFkZ0jsMkCnP6_A4jeoHu9y_iLtpqFq16CYZzU7yyIP4DquvLaw |
linkProvider | Library Specific Holdings |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+Surgical+Outcomes+Between+Invasive+Mucinous+and+Non-Mucinous+Lung+Adenocarcinoma&rft.jtitle=The+Annals+of+thoracic+surgery&rft.au=Matsui%2C+Takuya&rft.au=Sakakura%2C+Noriaki&rft.au=Koyama%2C+Shin&rft.au=Nakanishi%2C+Keita&rft.date=2021-10-01&rft.issn=0003-4975&rft.volume=112&rft.issue=4&rft.spage=1118&rft.epage=1126&rft_id=info:doi/10.1016%2Fj.athoracsur.2020.09.042&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_athoracsur_2020_09_042 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4975&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4975&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4975&client=summon |